Nucleos(t)ide reverse transcriptase inhibitors (NRTI) toxicity may represent a threat for long-term success of combined antiretroviral therapy. Some studies have suggested a possible improvement of NRTI-related toxicity after switching to NRTI-sparing regimens.
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL / Madeddu, Giordano; Rusconi, Stefano; Cozzi‑lepri, Alessandro; Di Giambenedetto, Simona; Bonora, Stefano; Carbone, Alessia; De Luca, Andrea; Gianotti, Nicola; Di Biagio, Antonio; Antinori, Andrea; Icona Foundation Study Group, The; Lichtner, Miriam; Mastroianni, Claudio Maria; Vullo, Vincenzo. - In: INFECTION. - ISSN 0300-8126. - ELETTRONICO. - (2017). [10.1007/s15010-017-1018-z]
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL
Miriam LichtnerMembro del Collaboration Group
;Claudio Maria MastroianniMembro del Collaboration Group
;Vincenzo VulloMembro del Collaboration Group
2017
Abstract
Nucleos(t)ide reverse transcriptase inhibitors (NRTI) toxicity may represent a threat for long-term success of combined antiretroviral therapy. Some studies have suggested a possible improvement of NRTI-related toxicity after switching to NRTI-sparing regimens.| File | Dimensione | Formato | |
|---|---|---|---|
|
Madeddu_Efficacy_2017.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
497 kB
Formato
Adobe PDF
|
497 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
